Journal of Disease Mechanisms and Genomics
Volume 1; Issue 1; May 2026

JDMG Journal of Disease Mechanisms and Genomics www.jdmg.org

Molecular Mechanisms of β-Cell Dysfunction and Insulin Resistance in Type 2 Diabetes Mellitus

Nadia Khan[a], Sohail Alam[b]

[a]*Department of Biological Sciences, UMT Lahore, Pakistan*
[b]*Instititute of Research, Peshawar University, Pakistan*
Correspondence: khnadia876233@gmail.com

Article history:
Received 25 March 2026
Accepted 28 April 2026
Published 7 May 2026

Keywords:
Type 2 diabetes mellitus; β-cell dysfunction; insulin resistance; oxidative stress; inflammation; mitochondrial dysfunction; metabolism

Abstract
Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder characterized by chronic hyperglycemia resulting from the progressive interplay between insulin resistance and pancreatic β-cell dysfunction. The global prevalence of T2DM continues to rise dramatically, representing a major public health burden associated with cardiovascular disease, nephropathy, neuropathy, retinopathy, and metabolic complications. Although insulin resistance initially develops in peripheral tissues including skeletal muscle, liver, and adipose tissue, progressive β-cell failure ultimately determines disease onset and long-term glycemic deterioration. Increasing evidence indicates that chronic inflammation, mitochondrial dysfunction, oxidative stress, glucolipotoxicity, endoplasmic reticulum stress, epigenetic remodeling, and immune-metabolic dysregulation collectively contribute to β-cell exhaustion and impaired insulin signaling. Advances in transcriptomics, metabolomics, single-cell sequencing, and multi-omics technologies have substantially improved the understanding of molecular heterogeneity and disease progression in T2DM. Furthermore, emerging studies reveal that β-cell dedifferentiation, impaired autophagy, altered gut microbiota, and chronic metaflammation play central roles in metabolic dysfunction and insulin resistance. Novel therapeutic strategies targeting inflammatory pathways, mitochondrial homeostasis, incretin signaling, cellular senescence, and epigenetic regulation are increasingly being explored for precision diabetes management. This review discusses the molecular mechanisms underlying β-cell dysfunction and insulin resistance in T2DM, emphasizing inflammatory remodeling, metabolic stress responses, and emerging translational opportunities for personalized therapeutic intervention.

1. Introduction

Type 2 diabetes mellitus (T2DM) represents one of the most prevalent chronic metabolic disorders worldwide and constitutes a major contributor to morbidity, mortality, and healthcare expenditure [1]. The disease is characterized by persistent hyperglycemia resulting from impaired insulin action combined with progressive pancreatic β-cell dysfunction [2]. According to the International Diabetes Federation, the global burden of diabetes continues to rise rapidly due to aging populations, sedentary lifestyles, obesity, and dietary transitions

associated with urbanization [3]. Long-term complications of T2DM include cardiovascular disease, nephropathy, neuropathy, retinopathy, non-alcoholic fatty liver disease, and increased susceptibility to infection [4].

Historically, insulin resistance and β-cell failure were often considered independent pathological processes. However, contemporary research demonstrates that these mechanisms are highly interconnected and evolve dynamically throughout disease progression [5]. Insulin resistance initially develops in peripheral metabolic tissues such as skeletal muscle, liver, and adipose tissue, leading to compensatory hyperinsulinemia in early disease stages [6]. Over time, chronic metabolic stress, inflammatory signaling, glucolipotoxicity, and oxidative injury progressively impair β-cell function and insulin secretory capacity, ultimately resulting in overt hyperglycemia [7].

Insulin resistance is characterized by reduced responsiveness of peripheral tissues to circulating insulin, resulting in impaired glucose uptake, increased hepatic gluconeogenesis, and altered lipid metabolism [8]. Skeletal muscle accounts for the majority of postprandial glucose disposal and is therefore a critical site of insulin action [9]. Defects in insulin receptor signaling, GLUT4 translocation, mitochondrial function, and intracellular metabolic pathways contribute substantially to impaired glucose utilization in insulin-resistant individuals [10].

Adipose tissue dysfunction also plays a central role in metabolic disease progression. Obesity-associated adipose expansion is accompanied by chronic low-grade inflammation, adipokine imbalance, hypoxia, immune cell infiltration, and altered lipid metabolism [11]. These processes collectively promote systemic insulin resistance through secretion of inflammatory cytokines, free fatty acids, and stress mediators that interfere with insulin signaling pathways [12]. Hepatic insulin resistance further exacerbates hyperglycemia through excessive glucose production and dysregulated lipid metabolism.

Pancreatic β-cells possess remarkable adaptive capacity during early insulin resistance by increasing insulin synthesis and secretion [13]. Nevertheless, prolonged metabolic stress eventually induces β-cell exhaustion, dedifferentiation, and apoptosis. Chronic exposure to elevated glucose and lipid concentrations, commonly referred to as glucolipotoxicity, contributes significantly to β-cell dysfunction through mitochondrial impairment, oxidative stress accumulation, endoplasmic reticulum stress, and inflammatory activation [14]. Mitochondrial dysfunction represents one of the central molecular mechanisms underlying both insulin resistance and β-cell failure [15]. Mitochondria regulate ATP generation, oxidative metabolism, calcium signaling, and reactive oxygen species production required for insulin secretion and cellular homeostasis [16]. In T2DM, impaired mitochondrial biogenesis, oxidative phosphorylation defects, and excessive oxidative stress disrupt metabolic flexibility and insulin signaling across multiple tissues [17].

Inflammation has also emerged as a major contributor to T2DM pathogenesis. Obesity-associated chronic low-grade inflammation, often termed metaflammation, involves activation of innate immune pathways, macrophage infiltration, inflammasome signaling, and cytokine secretion within metabolic tissues [18]. Pro-inflammatory mediators including TNF-α, IL-1β, and IL-6 impair insulin receptor signaling and contribute to β-cell injury [19]. Recent evidence additionally suggests that immune-metabolic dysregulation and inflammatory memory may sustain long-term metabolic dysfunction even following weight reduction. Endoplasmic reticulum (ER) stress further contributes to β-cell dysfunction and insulin resistance [20]. Pancreatic β-cells possess exceptionally high protein synthesis demands due to continuous insulin production, rendering them highly vulnerable to ER stress and unfolded protein responses. Chronic metabolic overload induces ER stress signaling pathways that impair insulin biosynthesis, promote inflammatory activation, and trigger apoptosis [21].

Epigenetic remodeling and non-coding RNA dysregulation additionally influence T2DM progression [22]. DNA methylation, histone modifications, chromatin remodeling, and microRNA-mediated regulation collectively modulate transcriptional programs associated with metabolism, inflammation, β-cell identity, and insulin sensitivity [23]. These epigenetic mechanisms may contribute to metabolic memory and long-term disease susceptibility. Recent advances in single-cell transcriptomics, metabolomics, proteomics, and systems biology have substantially improved understanding of cellular heterogeneity and disease evolution in T2DM [24]. Multi-omics technologies reveal remarkable diversity among β-cell populations, immune compartments, adipose tissue phenotypes, and metabolic signaling networks involved in

disease progression. Such approaches are facilitating identification of novel biomarkers and therapeutic vulnerabilities suitable for precision medicine strategies. Importantly, emerging therapeutic interventions targeting incretin pathways, inflammation, mitochondrial dysfunction, cellular senescence, gut microbiota, and epigenetic regulation are transforming modern diabetes management [25]. Continued investigation into the molecular interplay between β-cell dysfunction and insulin resistance is therefore essential for development of innovative precision therapeutic strategies capable of mitigating the growing global burden of T2DM.

2. Methodology

This review was conducted through a comprehensive literature search of peer-reviewed publications indexed in PubMed, Scopus, Web of Science, and Google Scholar databases. Relevant articles published primarily between 2000 and 2026 were identified using combinations of keywords including "type 2 diabetes mellitus", "β-cell dysfunction", "insulin resistance", "oxidative stress", "mitochondrial dysfunction", "glucolipotoxicity", "inflammation", "metaflammation", "epigenetics", "metabolomics", and "single-cell sequencing". Original research articles, systematic reviews, meta-analyses, and landmark mechanistic studies were prioritized. Particular emphasis was placed on studies investigating molecular interactions between insulin signaling abnormalities, inflammatory remodeling, metabolic dysfunction, and β-cell failure. Additional studies involving translational applications, therapeutic interventions, and precision medicine strategies were also included. References cited within selected publications were manually screened to ensure scientific relevance and comprehensive coverage of the topic.

3. Molecular Mechanisms Underlying Insulin Resistance and Metabolic Dysfunction in Type 2 Diabetes Mellitus

Insulin resistance represents a fundamental pathological hallmark of T2DM and precedes overt hyperglycemia by several years in many individuals [26]. The condition is characterized by impaired responsiveness of peripheral tissues to circulating insulin, resulting in defective glucose uptake, altered lipid metabolism, and excessive hepatic glucose production. Multiple molecular mechanisms contribute to insulin resistance, including inflammatory signaling, mitochondrial dysfunction, oxidative stress, lipid accumulation, and impaired intracellular insulin receptor signaling pathways. The insulin signaling cascade is initiated when insulin binds to the insulin receptor located on the surface of target cells [27]. Activation of insulin receptor substrate proteins (IRS-1 and IRS-2) subsequently stimulates phosphoinositide 3-kinase (PI3K) and Akt signaling pathways, ultimately promoting glucose transporter type 4 (GLUT4) translocation and glucose uptake [28]. In insulin-resistant states, serine phosphorylation of IRS proteins impairs downstream signaling and reduces insulin sensitivity.

Chronic low-grade inflammation constitutes a major driver of impaired insulin signaling in obesity-associated T2DM [29]. Adipose tissue expansion is accompanied by infiltration of pro-inflammatory macrophages and immune populations that secrete TNF-α, IL-6, MCP-1, and other cytokines capable of disrupting insulin receptor signaling [30]. Activation of inflammatory pathways including NF-κB, JNK, and inflammasome signaling promotes inhibitory phosphorylation of IRS proteins and metabolic dysfunction. Lipid accumulation within non-adipose tissues additionally contributes significantly to insulin resistance [31]. Elevated circulating free fatty acids and ectopic lipid deposition in liver and skeletal muscle induce lipotoxicity, oxidative stress, and mitochondrial dysfunction. Accumulation of ceramides and diacylglycerols activates stress kinases that impair insulin receptor signaling and glucose metabolism [32].

Mitochondrial dysfunction further amplifies metabolic abnormalities in insulin-resistant tissues. Reduced mitochondrial oxidative phosphorylation, impaired fatty acid oxidation, and excessive reactive oxygen species production contribute to defective energy metabolism and insulin sensitivity [33]. Skeletal muscle mitochondrial dysfunction is particularly important because muscle tissue accounts for the majority of insulin-mediated glucose disposal [34]. Oxidative stress also plays a central role in metabolic disease progression. Hyperglycemia and lipid overload increase mitochondrial reactive oxygen species generation, leading to oxidative damage of proteins, lipids, and nucleic acids [35]. Oxidative stress activates inflammatory signaling pathways, impairs insulin receptor function, and exacerbates cellular injury within metabolic tissues. The liver represents another critical organ involved in insulin resistance and glucose dysregulation. Hepatic insulin resistance promotes excessive gluconeogenesis, glycogen breakdown, and lipid synthesis, thereby contributing

substantially to fasting hyperglycemia and dyslipidemia [36]. Non-alcoholic fatty liver disease frequently coexists with T2DM and further aggravates systemic metabolic dysfunction.

Gut microbiota dysbiosis has also emerged as an important contributor to metabolic disease [37]. Altered microbial composition influences intestinal permeability, inflammatory signaling, bile acid metabolism, and short-chain fatty acid production. Metabolic endotoxemia resulting from increased lipopolysaccharide exposure may further amplify chronic inflammation and insulin resistance. Collectively, insulin resistance arises through highly interconnected molecular mechanisms involving inflammatory remodeling, mitochondrial dysfunction, oxidative stress, lipid toxicity, and immune-metabolic dysregulation. These pathological processes establish a progressively deteriorating metabolic environment that eventually overwhelms compensatory β-cell responses and promotes overt diabetes development.

4. β-Cell Dysfunction, Cellular Stress Responses, and Progressive Pancreatic Failure in Type 2 Diabetes Mellitus

Pancreatic β-cell dysfunction represents the decisive event leading to persistent hyperglycemia and clinical progression of T2DM [38]. Although insulin resistance may remain compensated for extended periods through increased insulin secretion, progressive β-cell failure ultimately impairs glycemic control and accelerates metabolic deterioration. Modern evidence indicates that β-cell dysfunction results from the cumulative effects of glucolipotoxicity, oxidative stress, inflammation, mitochondrial impairment, ER stress, and cellular dedifferentiation. β-cells possess exceptionally high metabolic and biosynthetic demands due to continuous insulin synthesis and secretion [39]. Consequently, these cells are particularly susceptible to oxidative injury and metabolic overload. Chronic exposure to elevated glucose concentrations induces glucotoxicity characterized by oxidative stress accumulation, mitochondrial dysfunction, and impaired insulin gene transcription [40]. Simultaneously, elevated free fatty acid levels promote lipotoxicity through ceramide accumulation, ER stress activation, and inflammatory signaling.

Mitochondrial dysfunction is among the earliest abnormalities detected in failing β-cells [41]. Mitochondria regulate ATP generation required for glucose-stimulated insulin secretion. Impaired oxidative phosphorylation, altered calcium signaling, and excessive reactive oxygen species production disrupt insulin exocytosis and β-cell survival [42]. Persistent oxidative stress further damages mitochondrial DNA and perpetuates metabolic dysfunction. Endoplasmic reticulum stress additionally contributes substantially to β-cell failure. Because β-cells synthesize large quantities of insulin, they rely heavily upon proper ER protein folding capacity [43]. Chronic metabolic overload activates the unfolded protein response (UPR), which initially serves adaptive functions but ultimately triggers inflammatory signaling and apoptosis under prolonged stress conditions [44]. Persistent ER stress therefore accelerates β-cell loss and secretory dysfunction.

Inflammation also directly contributes to pancreatic injury. Islet-associated macrophages and inflammatory cytokines including IL-1β, TNF-α, and IFN-γ impair insulin secretion and promote apoptosis [45]. NLRP3 inflammasome activation within pancreatic tissues has emerged as an important mechanism linking metabolic stress with inflammatory β-cell injury [46]. Recent studies additionally demonstrate that β-cell dedifferentiation contributes significantly to disease progression [47]. Rather than undergoing apoptosis exclusively, stressed β-cells may lose mature β-cell identity and revert toward progenitor-like states characterized by reduced insulin expression and altered transcriptional profiles. This cellular plasticity may represent an adaptive response to chronic metabolic stress but ultimately impairs functional insulin production.

Autophagy dysfunction further exacerbates β-cell vulnerability. Autophagy is essential for removal of damaged organelles, protein aggregates, and dysfunctional mitochondria [48]. Impaired autophagic flux contributes to oxidative stress accumulation, ER dysfunction, and defective insulin secretion in T2DM. Single-cell transcriptomic studies reveal remarkable heterogeneity among pancreatic β-cell populations [49]. Distinct β-cell subtypes exhibit variable metabolic capacity, stress responsiveness, proliferative potential, and insulin secretory function. Disease-associated β-cell states involving inflammatory signaling, senescence, and metabolic dysfunction become increasingly prevalent during T2DM progression.

Epigenetic remodeling additionally influences β-cell identity and function. DNA methylation abnormalities, histone modification imbalance, and microRNA dysregulation alter expression of genes involved in insulin synthesis, mitochondrial metabolism, inflammation, and cellular survival [50].

Such epigenetic alterations may contribute to metabolic memory and progressive β-cell deterioration. Collectively, β-cell dysfunction arises through complex interactions among metabolic stress, mitochondrial injury, inflammatory activation, ER stress, and epigenetic remodeling. Preservation of β-cell identity and functional resilience therefore remains a central therapeutic objective in T2DM management.

5. Inflammation, Epigenetic Remodeling, and Emerging Precision Therapeutic Strategies in Type 2 Diabetes Mellitus

Chronic low-grade inflammation, commonly referred to as metaflammation, is increasingly recognized as a fundamental driver of T2DM progression [51]. Unlike acute inflammatory responses, metaflammation develops gradually in response to nutrient excess, obesity, oxidative stress, and metabolic dysfunction. Persistent activation of innate immune pathways contributes substantially to insulin resistance, β-cell injury, vascular complications, and tissue remodeling. Adipose tissue inflammation plays central roles in metabolic disease pathogenesis. Obesity-associated adipocyte hypertrophy induces hypoxia, mechanical stress, and chemokine secretion that recruit macrophages and inflammatory immune populations into adipose tissue [52]. These immune cells secrete pro-inflammatory cytokines capable of disrupting insulin signaling across multiple tissues.

Inflammasome signaling has emerged as a particularly important mechanism linking metabolic stress with inflammation [53]. Activation of the NLRP3 inflammasome promotes IL-1β maturation and chronic inflammatory signaling associated with insulin resistance and β-cell dysfunction. Experimental inhibition of inflammasome pathways has demonstrated improved insulin sensitivity and reduced metabolic injury in preclinical studies. Epigenetic remodeling also contributes substantially to T2DM progression. DNA methylation patterns are altered in metabolic tissues of diabetic individuals, affecting genes associated with insulin signaling, inflammation, mitochondrial function, and glucose metabolism [54]. Histone acetylation and chromatin remodeling abnormalities further influence transcriptional programs involved in metabolic adaptation and immune responses.

MicroRNAs and long non-coding RNAs additionally regulate multiple metabolic pathways in T2DM [55]. Dysregulated microRNAs influence insulin receptor signaling, β-cell proliferation, inflammatory activation, and mitochondrial homeostasis. These epigenetic regulators are increasingly being explored as potential biomarkers and therapeutic targets. Recent advances in multi-omics technologies and systems biology are transforming precision diabetes research [56]. Integrative analyses combining genomics, transcriptomics, metabolomics, proteomics, and microbiome profiling permit comprehensive characterization of disease heterogeneity and therapeutic responsiveness. Artificial intelligence-assisted biomarker discovery is further facilitating personalized therapeutic strategies.

Modern therapeutic interventions increasingly target mechanisms beyond glucose lowering alone. GLP-1 receptor agonists and dual incretin therapies improve insulin secretion, reduce appetite, attenuate inflammation, and promote weight loss [57]. Sodium-glucose cotransporter-2 (SGLT2) inhibitors additionally provide cardiovascular and renal protection independent of glycemic effects. Mitochondrial-targeted therapies, antioxidant interventions, anti-inflammatory compounds, and senolytic approaches are also being actively investigated [58]. Emerging epigenetic therapies targeting chromatin remodeling, histone modifications, and inflammatory memory may further improve long-term metabolic outcomes.

Gut microbiota modulation through dietary intervention, probiotics, prebiotics, and microbial metabolite targeting additionally represents a promising therapeutic avenue [59]. Restoration of intestinal barrier integrity and microbial diversity may attenuate systemic inflammation and improve insulin sensitivity. Future precision medicine approaches in T2DM will likely integrate molecular profiling, wearable metabolic monitoring, AI-assisted predictive modeling, and individualized therapeutic selection [60]. Continued investigation into molecular disease mechanisms therefore remains essential for development of innovative interventions capable of mitigating the growing global burden of diabetes.

6. Conclusion

Type 2 diabetes mellitus is a highly complex metabolic disorder driven by dynamic interactions among insulin resistance, β-cell dysfunction, chronic inflammation, mitochondrial impairment, oxidative stress, and epigenetic remodeling. Contemporary evidence demonstrates that metabolic dysfunction extends far beyond simple glucose dysregulation and involves intricate immune-metabolic and cellular stress pathways across multiple organs. Insulin resistance within skeletal muscle, liver, and

adipose tissue establishes an adverse metabolic environment characterized by chronic inflammation, lipid toxicity, oxidative injury, and impaired insulin signaling. Progressive pancreatic β-cell dysfunction subsequently compromises compensatory insulin secretion and drives overt hyperglycemia. Importantly, β-cell failure is increasingly recognized as a multifactorial process involving glucolipotoxicity, mitochondrial dysfunction, ER stress, dedifferentiation, and inflammatory signaling.

Recent advances in single-cell sequencing, metabolomics, epigenomics, and systems biology have substantially improved understanding of molecular heterogeneity and disease progression in T2DM. These technologies are facilitating identification of novel biomarkers and therapeutic vulnerabilities suitable for precision medicine approaches. Emerging therapies targeting inflammation, mitochondrial dysfunction, incretin pathways, cellular senescence, and epigenetic regulation possess considerable translational potential for improving metabolic outcomes and reducing diabetic complications. Continued integration of molecular biology, computational medicine, immunometabolism, and translational therapeutics will therefore remain essential for advancing innovative precision strategies capable of mitigating the global burden of type 2 diabetes mellitus.

7. References

1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates. Diabetes Res Clin Pract. 2019;157:107843.
2. DeFronzo RA. From the triumvirate to the ominous octet. Diabetes. 2009;58(4):773–795.
3. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium; 2021.
4. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188.
5. Prentki M, Nolan CJ. Islet β-cell failure in type 2 diabetes. J Clin Invest. 2006;116(7):1802–1812.
6. Kahn SE. The relative contributions of insulin resistance and β-cell dysfunction. Diabetologia. 2003;46(1):3–19.
7. Weir GC, Bonner-Weir S. Five stages of evolving β-cell dysfunction. Diabetes. 2004;53(Suppl 3):S16–S21.
8. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223.
9. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance. Diabetes Care. 2009;32(Suppl 2):S157–S163.
10. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance. J Biomed Biotechnol. 2010;2010:476279.
11. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.
12. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–246.
13. Rhodes CJ. Type 2 diabetes-a matter of β-cell life and death? Science. 2005;307(5708):380–384.
14. Poitout V, Robertson RP. Glucolipotoxicity. Endocr Rev. 2008;29(3):351–366.
15. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307(5708):384–387.
16. Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic β-cells. Nature. 2001;414(6865):807–812.
17. Patti ME, Corvera S. The role of mitochondria in metabolic disease. Endocr Rev. 2010;31(3):364–395.
18. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.
19. Eguchi K, Manabe I. Macrophages and metabolic disease. J Mol Med. 2013;91(10):1141–1151.
20. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity and insulin resistance. Science. 2004;306(5695):457–461.
21. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress. Endocr Rev. 2008;29(1):42–61.
22. Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028–1044.
23. Dayeh T, Ling C. Does epigenetic dysregulation contribute to diabetic complications? Circ Res. 2015;116(1):104–116.
24. Segerstolpe Å, Palasantza A, Eliasson P, et al. Single-cell transcriptome profiling of human pancreatic islets. Cell Metab. 2016;24(4):593–607.
25. Drucker DJ. Mechanisms of action and therapeutic application of GLP-1. Cell Metab. 2018;27(4):740–756.